Delivering Nucleic Acids and Other Therapeutic Payloads for Cell, Gene and Immune Therapies

Delivering Nucleic Acids and Other Therapeutic Payloads for Gene and Immune Therapies

Our groundbreaking LNPs target extrahepatic organs and cells with low immunogenicity and toxicity

Our technology Proprietary Cell and Tissue-Targeted
Drug Delivery Systems (DDS)

Unique lipid nanoparticle (LNP) system incorporating natural gangliosides to replace PEG-lipid in conventional LNPs, offering targetability and reduced immunogenicity/toxicity.

Learn More

Sigfinity™

Lung-tropic lipoplex NPs (LPP) capable of delivering nucleic acids to the lung via systemic dosing.

Learn More

Zetafinity^®

Proprietary polymer nanoparticles (PNP) delivering small molecules, peptides, and proteins to immune cells for immunotherapy.

Learn More

Our Pipeline Nanoparticle Platforms

Learn More

Platforms	Class	Target
ZETAFINITY^®	PNP PNP	Antigen-Presenting Cells Antigen-Presenting Cells
Cytofinity™	LNP LNP LNP	Liver Lung Bone Marrow
Sigfinity™	LPP LPP	Lung Eye

Cour Pharmaceuticals

Cour/Takeda

WHO WE ARE Cytodigm is a biopharmaceutical company leveraging its next-generation DDS for cell, gene and immune therapies

ABOUT US

News Latest from
Cytodigm

Discover how it can revolutionize healthcare outcomes today.

view all

Cytodigm to Present at 3rd Annual LNP Immunogenicity & Toxicity Summit

In Boston, on December 11, 2024, Dr. Bin Wu, Cytodigm’s Founder and CEO, will present “Case Study: Building Next-Generation LNPs with Gangliosides Instead of PEG

Dec

Cytodigm Introduces Its PEG-Free Lipid Nanoparticles at LNP Summit

Boston, MA, December 11, 2023 – Victoria Trantow, R&D Scientist at Cytodigm, presented a poster titled “CytofinityTM PEG-free…

December

Cytodigm and Cour Sign Licensing Deal

Natick, MA, February 6, 2024 – Cytodigm, a biopharmaceutical company developing innovative delivery systems for nucleic acid therapeutics, announced…

Feb

Get more information about our technology